GefitinibDiarrhoea and acquired drug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1731卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55319-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：124 / 124

相关论文

共 50 条

[1] GefitinibDiarrhoea: case report
Reactions Weekly, 2015, 1582 (1) : 218 - 218
[2] GefitinibDiarrhoea and rash: case report
Reactions Weekly, 2017, 1675 (1) : 118 - 118
[3] AntineoplasticsNo response and acquired drug resistance: case report
Reactions Weekly, 2023, 1953 (1) : 57 - 57
[4] AntineoplasticsLack of drug effect and acquired resistance: case report
Reactions Weekly, 2022, 1888 (1) : 51 - 51
[5] AntineoplasticsLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2023, 1944 (1) : 83 - 83
[6] AntineoplasticsLack of efficacy and acquired drug resistance : case report
Reactions Weekly, 2024, 2018 (1) : 57 - 57
[7] Sintilimab/sorafenibRash and acquired drug resistance: case report
Reactions Weekly, 2022, 1926 (1) : 427 - 427
[8] AntineoplasticsLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2022, 1921 (1) : 36 - 36
[9] Antibacterials/antiretroviralsGI intolerance and acquired drug resistance: case report
Reactions Weekly, 2022, 1922 (1) : 60 - 60
[10] Antiretrovirals/AntiviralsLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2025, 2054 (1) : 61 - 61

← 1 2 3 4 5 →